Shorter chemo for slow-growing lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests whether a shorter, gentler course of chemotherapy (bendamustine plus rituximab) works just as well for slow-growing lymphomas like follicular lymphoma. The 'MRD-guided' part means the doctors will use a blood test to see if the cancer is gone, and they may stop treatment earlier if it is.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have one of these slow-growing lymphomas: follicular lymphoma, marginal zone lymphoma, or lymphoplasmacytic lymphoma.
- You are either newly diagnosed, or your lymphoma has come back after treatment, but you have not received bendamustine before.
- You are at least 18 years old.
- You are generally able to care for yourself (ECOG performance status 0-2).
- Your blood counts, liver, and kidney function are within acceptable limits.
- You have not had radiation or other lymphoma treatment in the 28 days before starting the study drugs.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a combination of chemotherapy and targeted drugs for people who have just been diagnosed with mantle cell lymphoma and haven't had any prior treatment (except short-term steroids or local radiation). It aims to see if adding newer targeted therapies can help keep the lymphoma in remission.
This trial tests whether giving a lower dose of radiation than usual works well for people with slow-growing B-cell lymphomas. It aims to reduce side effects while still controlling the disease.
This study tests a new way to treat slow-growing non-Hodgkin lymphoma that has come back or not responded to other treatments. It combines special immune cells with a targeted therapy to try to destroy cancer cells.
This trial tests a combination of two drugs, rituximab and CC-99282, as a first treatment for older adults with diffuse large b-cell lymphoma who are too frail for standard chemotherapy. The goal is to see if this gentler approach can effectively control the disease while being easier to tolerate.
This trial tests a combination of two targeted drugs (rituximab and zanubrutinib) for people with slow-growing B-cell lymphomas like marginal zone or follicular lymphoma. It may be a good option if you haven't had treatment for your lymphoma before and your disease needs therapy to manage symptoms.
This trial studies whether combining zanubrutinib and rituximab can better control indolent (slow-growing) mantle cell lymphoma. It aims to improve how long participants can stay without the lymphoma worsening.
Hear when a new Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.